



Translation only - Press Release made in Japan

January 30, 2012
Press Release

Immuno-Biological Laboratories Co., Ltd.
President, Tsutomu Seito

Immuno-Biological Laboratories Co., Ltd. and Takara Bio Inc. enter to sign a distribution agreement for IBL research use only (RUO) products

Please to announce that Immuno-Biological Laboratories Co., Ltd. ("IBL") has adopted a resolution entering to sign a distribution agreement which IBL grants to Takara Bio Inc ("Takara Bio") a right of distributing IBL research use only (RUO) products and its customized services exclusively in Japan and non-exclusively in other countries worldwide in board meeting held on today January 30, 2012.

By entering this agreement, synergy effects for expanding sales and marketing activities utilizing Takara Bio's broad distribution network in worldwide for both parties can be expected since Takara Bio's product lineup which is mainly covered for gene engineering and cellular biological field will be strengthened and become more varieties by adding IBL RUO products such as antibodies, ELISA kits and its customized services on their product lineup. Entering this agreement also enable IBL to more concentrate and focus on their research and development work for newly developed commercial products and finding novel technologies in future.

About Takara Bio

Since Takara Bio started to sell restriction enzyme which was introduced nation first in 1979, Takara Bio has been developing and supplying a broad range of product lineup inclusive PCR used in gene engineering field which fulfill market needs. In Recent year, Takara Bio has been expanding their development in cell biological field such as analysis gene function and induced pluripotent stem cell ("iPS cell"). Takara Bio has also their strong distribution network in USA and Europe and they have been also expanding their network in emerging countries such as China and India. For additional information, please visit <http://www.takara-bio.com/>

About IBL

IBL has been working on research and development of various antibodies which are recognized as fundamental research tools in biological technology filed since IBL was established in 1982. IBL has especially strong advantageous skills and know how in particular fields such as cancer, cerebral nerve related diseases, diabetes, fat metabolism related diseases and IBL has a broad range of RUO product lineup such as antibodies and ELISA kits used in these research field. IBL also provides a high quality of customized services for producing of antibodies. Thus IBL pursues development of antibodies and aim to develop its business into diagnostic and medical field. For additional information, please visit <http://www.ibl-japan.co.jp/eng/index.htm>

For further information contact:

Immuno Biological Laboratories Co., Ltd.

Dr. Noriaki Kinoshita
Director of Business Administration and the Head of
Manufacturing / Product Development Department
Tel: +81-274-22-2889 Fax: +81-274-23-6055